Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.

Autor: Samtsov AV; Department of Dermatology, S.M. Kirov Military Medical Academy, Saint-Petersburg, Russia., Bakulev AL; Department of Dermatology, V.I. Razumovskiy Saratov State Medical University, Saratov, Russia., Khairutdinov VR; Department of Dermatology, S.M. Kirov Military Medical Academy, Saint-Petersburg, Russia., Kokhan MM; Scientific Clinical Department, Ural Research Institute of Dermatovenereology and Immunopathology, Yekaterinburg, Russia., Korotaeva TV; Spondyloarthritis and Psoriatic Arthritis Laboratory, V.A. Nasonova Research Institute for Rheumatology, Moscow, Russia., Minullin IK; Head of Institution, Republican Clinical Dermatology and Venereology Clinic, Kazan, Russia., Vylegzhanina OA; Diagnostic Center, Siberian Regional Medical Center of the Federal Medical and Biological Agency, Novosibirsk, Russia., Dubenskiy VV; Dermatovenerology Department, Tver State Medical University, Tver, Russia., Khalilov BV; Dermatovenerology Department, Kazan State Medical University, Kazan, Russia., Khotko AA; Department of Dermatology, Clinical Dermatology and Venereology Clinic of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russia., Zykova OS; Department of Dermatology, Vitebsk Regional Clinical Center for Dermatology, Venereology and Cosmetology, Vitebsk, Republic of Belarus., Chumachenko IV; Department of Dermatology, Mogilev Regional Dermatology and Venereology Clinic, Mogilev, Republic of Belarus., Lukyanov AM; Department of Dermatology, City Clinical Dermatology and Venereology Clinic, Minsk, Republic of Belarus., Artemeva AV; Clinical research department, JSC BIOCAD, Saint Petersburg, Russia., Pukhtinskaia PP; Clinical research department, JSC BIOCAD, Saint Petersburg, Russia.

Publikováno v: PloS one [PLoS One] 2022 Feb 07; Vol. 17 (2), pp. e0263214. Date of Electronic Publication: 2022 Feb 07 (Print Publication: 2022).